Targeted contrast agents--an adjunct to whole-body imaging: current concepts.

This article reviews the potential use of a combination of whole-body imaging and targeted contrast agents in improving diagnostics, with a particular focus on oncology imaging. It looks at the rationale for nanoparticles and their development as targeted contrast agents. It subsequently describes many of the advances made thus far in developing tissue-specific contrast agents capable of targeting tumors that combined with whole-body imaging may enable superior cancer detection and characterization.

[1]  S. Ferrini,et al.  Two-Step In Vivo Tumor Targeting by Biotin-Conjugated Antibodies and Superparamagnetic Nanoparticles Assessed by Magnetic Resonance Imaging at 1.5 T , 2010, Molecular Imaging and Biology.

[2]  Jacek Capala,et al.  Changes in HER2 Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and 18F-Labeled Affibody Molecules , 2009, Journal of Nuclear Medicine.

[3]  Jinnian Peng,et al.  Targeted delivery of insulin-modified immunoliposomes in vivo , 2009, Journal of liposome research.

[4]  Chien-Hsun Wu,et al.  A Novel Peptide Enhances Therapeutic Efficacy of Liposomal Anti-Cancer Drugs in Mice Models of Human Lung Cancer , 2009, PloS one.

[5]  V. Torchilin,et al.  Enhanced tumor MR imaging with gadolinium‐loaded polychelating polymer‐containing tumor‐targeted liposomes , 2008, Journal of magnetic resonance imaging : JMRI.

[6]  Xu Wang,et al.  Application of Nanotechnology in Cancer Therapy and Imaging , 2008, CA: a cancer journal for clinicians.

[7]  L. Martiniova,et al.  [18F]FBEM-ZHER2:342-Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  J. Dufour,et al.  Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2 , 2007, Journal of drug targeting.

[9]  S. Eustace,et al.  Whole body MR imaging: applications in oncology. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  V. Torchilin,et al.  Gadolinium-Loaded Polychelating Polymer-Containing Cancer Cell-Specific Immunoliposomes , 2006, Journal of liposome research.

[11]  Philip S Low,et al.  Folate receptor-mediated drug targeting: from therapeutics to diagnostics. , 2005, Journal of pharmaceutical sciences.

[12]  K. Nicolay,et al.  Relaxivity of liposomal paramagnetic MRI contrast agents , 2005, Magnetic Resonance Materials in Physics, Biology and Medicine.

[13]  Hiroyuki Honda,et al.  Medical application of functionalized magnetic nanoparticles. , 2005, Journal of bioscience and bioengineering.

[14]  M. Follen,et al.  Molecular imaging of carcinogenesis with immuno-targeted nanoparticles , 2004, The 26th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[15]  S. Sahoo,et al.  Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer , 2004, International journal of cancer.

[16]  K. Nicolay,et al.  A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. , 2004, Bioconjugate chemistry.

[17]  Tae Gwan Park,et al.  Folate receptor targeted biodegradable polymeric doxorubicin micelles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Sanjiv S Gambhir,et al.  124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Dmitri Artemov,et al.  Magnetic resonance molecular imaging of the HER-2/neu receptor. , 2003, Cancer research.

[20]  Wolfgang Ebert,et al.  Tissue-specific MR contrast agents. , 2003, European journal of radiology.

[21]  Dmitri Artemov,et al.  MR molecular imaging of the Her‐2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles , 2003, Magnetic resonance in medicine.

[22]  Roy Bicknell,et al.  The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. , 2002, Cancer research.

[23]  Ulrik B Nielsen,et al.  Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  Jo Klaveness,et al.  Liposomes as carriers of amphiphilic gadolinium chelates: the effect of membrane composition on incorporation efficacy and in vitro relaxivity. , 2002, International journal of pharmaceutics.

[25]  H. Maeda,et al.  Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[26]  H. Yanagie,et al.  Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.

[27]  S. P. Vyas,et al.  Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization. , 2001, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[28]  R. Kerbel.  Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[29]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[30]  H Honda,et al.  Development of a target-directed magnetic resonance contrast agent using monoclonal antibody-conjugated magnetic particles. , 1996, Noshuyo byori = Brain tumor pathology.

[31]  G. Neufeld,et al.  Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants , 1996, Cancer and Metastasis Reviews.

[32]  R Weissleder,et al.  Targeted contrast agents in MR imaging. , 1996, Magnetic resonance imaging clinics of North America.

[33]  F. Martin,et al.  Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. , 1992, Cancer research.

[34]  Ernest K. J. Pauwels,et al.  Nanoparticles in Cancer , 2008 .

[35]  L. Martiniova,et al.  tracer for in vivo monitoring of HER2 expression by positron emission tomography , 2008 .

[36]  E. Gianolio,et al.  Innovative magnetic resonance imaging diagnostic agents based on paramagnetic Gd(III) complexes. , 2002, Biopolymers.

[37]  John W. Park,et al.  Immunoliposomes for cancer treatment. , 1997, Advances in pharmacology.

[38]  V. Torchilin,et al.  A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. , 1997, Oncology research.

[39]  Torchilin Vp,et al.  A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. , 1997 .

[40]  L. Seymour.  Passive tumor targeting of soluble macromolecules and drug conjugates. , 1992, Critical reviews in therapeutic drug carrier systems.